WEKO3
インデックスリンク
アイテム
製薬企業の研究開発投資と業績の関係に関する一考察
https://doi.org/10.15085/00000072
https://doi.org/10.15085/000000720c08f992-bea0-450d-b0f7-251ea9477a9a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00004857894.pdf (1.3 MB)
|
|
| アイテムタイプ | [ELS]紀要論文 / Departmental Bulletin Paper(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2006-01-01 | |||||||||||
| タイトル | ||||||||||||
| タイトル | 製薬企業の研究開発投資と業績の関係に関する一考察 | |||||||||||
| 言語 | ja | |||||||||||
| タイトル | ||||||||||||
| タイトル | Consideration about Relations of a R & D Investment and Achievements : a Case Study of Japanese Ethical Drug Companies | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | jpn | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | 医薬品産業｜研究開発投資｜投資利益率｜製品ライフサイクル | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | pharmaceutical industry｜R & D investment ｜return on investment (ROI)｜product life cycle | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||
| ID登録 | ||||||||||||
| ID登録 | 10.15085/00000072 | |||||||||||
| ID登録タイプ | JaLC | |||||||||||
| 雑誌書誌ID | ||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||
| 収録物識別子 | AA11345848 | |||||||||||
| 雑誌書誌ID | ||||||||||||
| 関連タイプ | isPartOf | |||||||||||
| 識別子タイプ | ISSN | |||||||||||
| 関連識別子 | 1344-607X | |||||||||||
| 言語 | ja | |||||||||||
| 関連名称 | 宮城大学事業構想学部紀要 | |||||||||||
| 著者 |
高橋, 義仁
× 高橋, 義仁
|
|||||||||||
| 著者所属(日) | ||||||||||||
| 宮城大学事業構想学部事業計画学科 | ||||||||||||
| 記事種別(日) | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | 論文 | |||||||||||
| 記事種別(英) | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | Article | |||||||||||
| 抄録(英) | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | Drugs have a clear-cut life cycle. The key to the growth of a pharmaceutical company, therefore, is to consider how to make R & D projects a success and deliver new products to the market. This paper uses a long-term survey to report on the influence that investments in new product development have on corporate sales and profits. As the first theme of my paper, I selected approximately 648 high-grossing prescription drugs that were sold in Japan in 2000, and investigated the year in which they were released as a new product. Results showed that sales of prescription drugs peaked from 5 to 15 years after their launch. As the second theme of my paper, I focused on the relationship between research fees and corporate growth capabilities. At present, drugs that have been developed in Europe and the US are steadily increasing their shares in Japan's prescription drug market. This is often explained as being attributable to differences in R & D spending. I therefore studied how such differences in R & D spending affect a company's subsequent development capabilities and sales growth by analyzing the R & D expenses, sales and ordinary profit, between 1983 and 2000, of 34 high-ranking Japanese pharmaceutical companies. During this period, the rate of R & D spending on sales showed a rising trend. The average correlation coefficient of R & D spending and sales covering the period from one year after release to 17 years later ranged from r=0.92 to r=0.86, showing a high correlation. Standard deviation (σ) that shows the dispersion of the correlation coefficient for each year dropped to σ=0.008 four and five years after product launch, which was the lowest level throughout the period studied. The average correlation coefficient of R & D spending and ordinary profit, meanwhile, ranged from r=0.86 to r=0.75, confirming that an equally high correlation had continued. It appears that the rising proportion of funds directed at R & D is indicative of corporations implementing R & D projects on an ever larger scale to adapt to what is becoming an increasingly complex environment. R & D spending and sales converged four to 5 years after release while showing a high correlation. One reason for this is the huge costs required at the final stage of R & D. Another may be that, considering the fact that it takes about 5 years to launch a new product, increases and decreases in R & D spending greatly affected sales levels five years later. Conclusion: This study shows that a strong and long-term correlation exists between R & D expenses and sales/profits. Investments in R & D in the pharmaceutical industry are therefore essential to maintain sales. | |||||||||||
| 書誌情報 |
ja : 宮城大学事業構想学部紀要 巻 9, p. 53-64 |
|||||||||||
| 表示順 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | 10 | |||||||||||
| アクセション番号 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | KJ00004857894 | |||||||||||
